{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:41:54Z","timestamp":1794577314182,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.anai.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:23:37Z","timestamp":1784042617000},"page":"579-587.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["High systemic corticosteroids burden among patients with moderate-to-severe asthma in the United States"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-7105","authenticated-orcid":false,"given":"Njira L.","family":"Lugogo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Katial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mena","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Tardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.07.006_bib0001","series-title":"Global strategy for asthma management and prevention","year":"2025"},{"key":"10.1016\/j.anai.2026.07.006_bib0002","series-title":"Most recent national asthma data","year":"2025"},{"issue":"7","key":"10.1016\/j.anai.2026.07.006_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101066","article-title":"Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR)","volume":"18","author":"Schleich","year":"2025","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.anai.2026.07.006_bib0004","series-title":"Global Strategy for Asthma Management and Prevention","year":"2026"},{"issue":"4","key":"10.1016\/j.anai.2026.07.006_bib0005","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the International Severe Asthma Registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.anai.2026.07.006_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02363-2019","article-title":"Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK","volume":"55","author":"Tran","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.07.006_bib0007","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaip.2020.06.019","article-title":"Oral corticosteroid treatment patterns of patients in the United States with persistent asthma","volume":"9","author":"Tran","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.07.006_bib0008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.anai.2021.09.025","article-title":"Mapping geographic variability of severe uncontrolled asthma in the United States: management implications","volume":"128","author":"Bleecker","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.anai.2026.07.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015905","article-title":"Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France","volume":"7","author":"B\u00e9nard-Laribi\u00e8re","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.anai.2026.07.006_bib0010","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2026.07.006_bib0011","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/PPA.S303841","article-title":"Therapeutic inertia in prescribing biologics for patients with moderate-to-severe asthma: workshop summary","volume":"15","author":"Sico","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"10.1016\/j.anai.2026.07.006_bib0012","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3390\/medicina61101797","article-title":"Early initiation of biologic therapies to prevent severe asthma progression","volume":"61","author":"Tomasello","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"10.1016\/j.anai.2026.07.006_bib0013","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4187\/respcare.03200","article-title":"Asthma and adherence to inhaled corticosteroids: current status and future perspectives","volume":"60","author":"B\u00e5rnes","year":"2015","journal-title":"Respir Care"},{"key":"10.1016\/j.anai.2026.07.006_bib0014","series-title":"National Historical Geographic Information System. version 12.0","author":"Manson","year":"2015"},{"issue":"6","key":"10.1016\/j.anai.2026.07.006_bib0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1047-2797(01)00221-6","article-title":"Area characteristics and individual-level socioeconomic position indicators in three population-based epidemiologic studies","volume":"11","author":"Diez-Roux","year":"2001","journal-title":"Ann Epidemiol"},{"issue":"5","key":"10.1016\/j.anai.2026.07.006_bib0016","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaci.2017.07.014","article-title":"More than a decade follow-up in patients with severe or difficult-to-treat asthma: the Epidemiology and Natural History of Asthma: outcomes and Treatment Regimens (TENOR) II","volume":"141","author":"Chipps","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.07.006_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/02770903.2016.1194430","article-title":"Measuring the cost of poor asthma control and exacerbations","volume":"54","author":"Sullivan","year":"2017","journal-title":"J Asthma"},{"issue":"11","key":"10.1016\/j.anai.2026.07.006_bib0018","first-page":"1117","article-title":"Patient outcomes, health care resource use, and costs associated with high versus low HEDIS asthma medication ratio","volume":"23","author":"Luskin","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.anai.2026.07.006_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1710-1492-9-27","article-title":"Electronic health record-based assessment of oral corticosteroid use in a population of primary care patients with asthma: an observational study","volume":"9","author":"Allen-Ramey","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.07.006_bib0020","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/02770903.2022.2082305","article-title":"Over-prescription of short-acting \u03b2(2)-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study","volume":"60","author":"Montero-Arias","year":"2023","journal-title":"J Asthma"},{"issue":"6","key":"10.1016\/j.anai.2026.07.006_bib0021","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaip.2014.07.016","article-title":"Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis","volume":"2","author":"Tunceli","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2026.07.006_bib0022","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.anai.2026.07.006_bib0023","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"12","key":"10.1016\/j.anai.2026.07.006_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"9","key":"10.1016\/j.anai.2026.07.006_bib0025","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/thorax-2022-219642","article-title":"Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma","volume":"78","author":"Heatley","year":"2023","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.anai.2026.07.006_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100760","article-title":"The use of systemic corticosteroids in asthma management in Latin American countries","volume":"16","author":"Maspero","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.anai.2026.07.006_bib0027","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with Benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2026.07.006_bib0028","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-022-01714-5","article-title":"Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma","volume":"28","author":"Kachroo","year":"2022","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.anai.2026.07.006_bib0029","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1164\/rccm.201810-1868CI","article-title":"Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology","volume":"199","author":"Beasley","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.07.006_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s41030-017-0043-5","article-title":"A review on the safety and efficacy of inhaled corticosteroids in the management of asthma","volume":"3","author":"Ye","year":"2017","journal-title":"Pulm Ther"},{"issue":"2","key":"10.1016\/j.anai.2026.07.006_bib0031","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaip.2022.10.040","article-title":"Effect of stepping up to high-dose inhaled corticosteroids in patients with Asthma: UK Database Study","volume":"11","author":"Pavord","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2026.07.006_bib0032","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.jaip.2024.03.018","article-title":"Gaps in care among uncontrolled severe asthma patients in the United States","volume":"12","author":"Carr","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2026.07.006_bib0033","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/JAA.S134300","article-title":"Asthma referrals: a key component of asthma management that needs to be addressed","volume":"10","author":"Price","year":"2017","journal-title":"J Asthma Allergy"},{"issue":"10","key":"10.1016\/j.anai.2026.07.006_bib0034","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1016\/j.jaip.2021.05.003","article-title":"Real-world assessment of asthma specialist visits among U.S. patients with severe asthma","volume":"9","author":"Most","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2026.07.006_bib0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/all.13556","article-title":"Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma","volume":"74","author":"Voorham","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.07.006_bib0036","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/13696998.2025.2477877","article-title":"Adverse consequences of systemic corticosteroids use among a broad population of US adults with asthma: a real-world analysis","volume":"28","author":"Wu","year":"2025","journal-title":"J Med Econ"},{"issue":"4","key":"10.1016\/j.anai.2026.07.006_bib0037","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?","volume":"122","author":"Anderson III","year":"2019","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T15:50:08Z","timestamp":1794498608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626003364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1081120626003364"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.006","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High systemic corticosteroids burden among patients with moderate-to-severe asthma in the United States","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}